Asbestos Exposure Biomarkers in the Follow-up of Asbestos-Exposed Workers

Valentina PAOLUCCI, Department of Medical Biotechnology, University of Siena, Viale Bracci 16, 53100 Siena, Italy

Riccardo ROMEO, Unit of Occupational Health Azienda Ospedaliera Universitaria Senese, Viale Bracci 16, 53100 Siena, Italy

Antonietta Gerardina SISINNI, Unit of Occupational Health Azienda Ospedaliera Universitaria Senese, Viale Bracci 16, 53100 Siena, Italy

Giuseppina SCANCARELLO, Unit of Occupational Hygiene and Toxicology, Laboratory of Public Health AUSL South-East Tuscany, Strada del Ruffolo 4, 53100 Siena, Italy

Luca VOLTERRANI, Department of Medical Surgical and Neurological Science, University of Siena, Unit of Diagnostic Imaging Azienda Ospedaliera Universitaria Senese, Viale Bracci 16, 53100 Siena, Italy

Maria Antonietta MAZZEI, Department of Medical Surgical and Neurological Science University of Siena, Unit of Diagnostic Imaging Azienda Ospedaliera Universitaria Senese, Viale Bracci 16, 53100 Siena, Italy

Lucio BARABESI, Department of Economics and Statistics, University of Siena, Piazza San Francesco 7, 53100 Siena, Italy

Pietro SARTORELLI, Department of Medical Biotechnology, University of Siena, Unit of Occupational Health Azienda Ospedaliera Universitaria Senese, Viale Bracci 16, 53100 Siena, Italy

Corresponding Author: Prof. Pietro Sartorelli, Department of Medical Biotechnology, University of Siena, Unit of Occupational Health Azienda Ospedaliera Universitaria Senese, Viale Bracci 16, 53100 Siena, Italy

Phone Number: +390577586755

Fax Number: +390577586159

E-Mail: pietro.sartorelli@unisi.it

Running Title: ASBESTOS EXPOSURE BIOMARKERS IN EXPOSED WORKERS
Abstract

Health surveillance of asbestos exposed workers should be stratified according to the exposure level. Unfortunately there is a lack of information regarding asbestos exposure in many working places and markers of asbestos exposure are often needed. The aim of the study was to assess the reliability of different dose and effect biomarkers in the follow up of asbestos-exposed workers.

Mineralogical analysis of bronchoalveolar lavage fluid (BALF) as a biomarker of asbestos fibre burden was performed in a population of 307 male subjects occupationally exposed to asbestos. Using nonparametric statistical methods 8 variables were analyzed with respect to asbestos-related diseases and working sectors. The existence of a relationship between serum soluble mesothelin-related peptides (SMRP) and asbestos exposure levels was also investigated.

Concentrations of amphiboles, chrysotile and asbestos bodies in BALF were higher in patients with asbestosis as well as in railway industry workers. A correlation between the onset of non malignant asbestos-related diseases and the levels of SRMP concentration was not found.

This study confirms that fibre concentration in BALF may be considered as a reliable biomarker of previous asbestos exposure, whereas SRMP does not appear to be influenced by asbestos exposure levels.

Key words: asbestos, amphibole, asbestosis, biomarkers, bronchoalveolar lavage, mesothelin

INTRODUCTION

Health surveillance of asbestos exposed workers is mandatory in many countries. The Helsinki Declaration on Management and Elimination of Asbestos-Related Diseases adopted by the International Conference on Monitoring and Surveillance of Asbestos-Related Diseases stated that, in view of the long latency period of asbestos-related diseases, health monitoring should continue after exposure has stopped, and among workers who may have changed job or retired. A general follow-up routine of asbestos-exposed workers should be stratified according to the intensity, latency and duration of exposure. A reliable work history could provide an useful measure of occupational asbestos exposure. However there is a lack of information regarding asbestos exposure (i.e. airborne fibre concentration and pattern of exposure) in many workplaces and biomarkers of asbestos exposure are often needed. Previous studies demonstrated that mineralogical analysis of bronchoalveolar lavage fluid (BALF) can represent a suitable method for the in vivo assessment of asbestos lung burden. On the other hand cancer biomarkers like serum soluble mesothelin-related peptides (SMRP) were
proposed for early diagnosis of neoplastic asbestos-related diseases\textsuperscript{6-9)} even if currently none of these seem sufficiently sensitive and specific for diagnostic or screening purposes\textsuperscript{1). The aim of the study was to assess the reliability of mineralogical analysis of BALF as a marker of previous exposure to asbestos characterizing asbestos exposure in different working sectors and comparing exposure levels related to the different asbestos diseases. The existence of a possible relationship between SMRP and asbestos exposure levels was also investigated.

**SUBJECTS AND METHODS**

**Subjects**

The occupationally exposed population consisted of 307 male workers (mean age 57 yrs, range 41-81) hospitalized from 2007 to 2013 in the Occupational Medicine Unit of the University Hospital of Siena for suspected asbestos-related diseases. With regard to the smoking habit 33% out of them were non smokers, 48% former smokers with a mean of 17 packs/yr and 19% smokers with a mean of 22 packs/yr. According to the occupational history 8 main industrial activities were singled out: 20% railway industry (insulation removal and rolling stock production), 6% shipbuilding yards, 13% building industry, 11% metal foundry, 18% engineering industry, 8% transport (flight attendants, subway workers), 19% electric energy production, 5% other industries (typography, sugar refinery, glassware). A non professionally exposed population was randomly selected to determine the fibre concentration in BALF with respect to the values in occupationally exposed workers. Biological samples were obtained by a population of patients who from 2014 to 2015 underwent to a diagnostic fibreoptic bronchoscopy in the Pneumology Unit of the University Hospital of Siena for non malignant diseases. Following current diagnostic criteria, chest X-ray and High Resolution Computed Tomography (HRCT) were performed to evaluate the presence of asbestos-related diseases. Non malignant asbestos-related diseases were diagnosed following the American Thoracic Society (ATS) criteria\textsuperscript{10). Moreover patients underwent pulmonary functional tests (PFTs), serum SMRP concentration dosage and bronchoscopy with mineralogical analysis of BALF to determine the asbestos lung burden. Considering the lag time from the first exposure to asbestos to the bronchoalveolar lavage (BAL) analysis, patients were split into three groups (≤20 yrs, between 20 and 40 yrs, between 40 and 60 yrs). Taking into account the lag time between the last exposure to asbestos and BAL, they were divided into three groups (≤10 yrs, between 10 and 20 yrs, between 20 and 30 yrs). PFTs were performed according to standard ATS 1987 and results were compared to CECA 1971 reference values. SMRP
concentrations were determined by using Mesomark (CISbio International) according to the manufacturer’s instructions.

With the regard to the sample of subjects non occupationally exposed to asbestos, according to the schedule approved by the Ethics Hospital Committee each patient before the examination provided the consent to take a sample of BALF for the mineralogical analysis and filled out a medical and professionally history questionnaire.

On the bases of the results of the questionnaire patients with diagnosis of an interstitial lung disease, an occupational lung disease and an asbestos exposure were not enrolled. Following these criteria to avoid selection bias for exposition or pathology only 21 patients (17 male and 4 female, mean age 63 yrs, range 37-81) were selected. This group cannot be considered a statistical control group for the remarkable differences into the two populations due to the random selection.

Chest CT

HRCT examination consisted of a series (57 images) of 0.625mm sections separated by 10mm gaps, obtained in axial scanning mode (0.625/4 images row, 1:10mm stop and shoot) using a 64 multidetector CT (VCT, General Electric Healthcare, Milwaukee, USA). The following parameters were used: subject position: prone; breathing instructions: suspended full inspiration; scanning mode: axial; display FOV: to encompass lungs at the largest anatomical location; interval: 10mm; collimation 0.625mm; reconstruction algorithm: high spatial frequency (bone plus); kV: 140; mAS: 330; time per tube rotation: 0.8s; intravenous contrast medium: none. Scanning was performed from the base to apex of the lung in order to avoid diaphragmatic movements.

A standard reconstruction algorithm was also used to evaluate pleural alteration.

All the 307 CT examinations were retrospectively analysed by a Radiologist with more than 10 yrs of experience in thoracic imaging. The cases were randomly presented to the reader without any BALF data and clinical information. The CT examinations were evaluated for evidence of pleural plaques and parenchymal abnormalities according to The International Classification of High resolution CT for Occupational and Environmental Respiratory Diseases (ICOERD)\textsuperscript{11}). A sum grade of \( \geq 2\)-3 bilateral irregular opacities in lower zones according to the reference film or bilateral honeycombing (sum grade \( \geq 2\)) would be sufficient to represent fibrosis according to the ICOERD system\textsuperscript{11}). Subpleural curvilinear lines or dots, both findings of bronchiolar fibrosis at HRCT, were also considered as signs of asbestosis.

Mineralogical analysis of BALF

Asbestos bodies (AB) in BALF were counted with a phase contrast microscope at a magnification of x250 following the method described by De Vuyst\textsuperscript{12}). Ten ml of BALF were used for asbestos fibre counting with
Scanning Electron Microscope (SEM) at a magnification of x10,000. The samples were filtered onto a 0.45 µm Millipore filter. All reagents were pre-filtered onto a 0.22 µm Millipore filter to avoid asbestos contamination. The sample was treated following the Dodson method\(^{13}\). Only particles with an aspect ratio of 3:1 or more were counted not using the lower limits of length and diameter. The detection limit was <160 fibres/ml BALF.

**Statistical analysis**

In the studied population 8 variables were considered (Table 1) with respect to two factors (i.e. asbestos-related diseases and working sectors). For non malignant asbestos-related diseases workers were divided into 3 groups (i.e. pleural plaques, pleural plaques and asbestosis, no pathology), while considering working activities the studied population was split into 8 sectors (i.e. railway industry, shipbuilding yards, building industry, metal foundry, engineering industry, transports, electric energy production, other industries).

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
</table>

In a proper statistical setting, therefore we require for two separate MANOVA corresponding to each factor, with the aim of assessing if a different behaviour occurs with respect to the factors. Since some variables were discrete, an ordinary application of MANOVA testing based on Hotelling statistic was not suitable, because multivariate normality of the joint variable distribution does not hold. In this case, we have opted for a nonparametric approach to MANOVA. Thus the previously described\(^4\) permutation testing procedure was applied which avoid the normality assumption and in addition allows for testing the items of the factor that eventually led to the refusal of the global null hypothesis (i.e. no effect of the factor)\(^{14}\). In addition, for each sector the confidence intervals for the corresponding population means were computed by adopting the bias-corrected and accelerated (BCa) bootstrap, as proposed by Efron\(^{15}\). The bootstrap technique was adopted since a parametric approach does not seem suitable for modelling this data and hence a nonparametric technique is more appropriate. Moreover, the BCa bootstrap was chosen since it adjust for both bias and skewness in the bootstrap distribution and produces reasonably narrow intervals.

Statistical comparison between the results of the mineralogical analysis of BALF between the group of non asbestos exposed and professionally exposed patients was not possible because of the remarkable differences into the two groups (in particular regarding the sample size and genre).

**RESULTS**

On the basis of the radiological and clinical study in 132 patients (43%) a non malignant asbestos related disease was diagnosed. 85 of them had pleural plaques, 2 subjects were affected by asbestosis and in 45 cases pleural
plaques and asbestosis were both present. In Figure 1 the distribution of asbestos diseases divided for working sectors is shown.

Figure 1

Figure 2 shows the concentrations of amphiboles, chrysotile and total asbestos fibres in BALF of professionally exposed workers grouped for working sectors. The highest percentage of asbestos-related diseases was found in the railway industry according to the upper average of asbestos fibres and AB concentrations in BALF. At the same time the transport workers, who have not asbestos diseases, presented the lowest concentration in the BALF of all biomarkers.

Figure 2

Statistical analysis applied to the different groups of asbestos diseases rejected the overall null hypothesis, and the rejection was due mainly to the lag time from the last exposure and the concentration of amphiboles in BALF (p-value <0.001) and in a lesser extent to chrysotile (p-value = 0.04) and AB concentration in BALF (p-value = 0.02).

The same analysis when was applied to the different working sectors rejected the overall null hypothesis (p-value <0.001). Also in this case the rejection was mainly due to the years from the last asbestos exposure (p-value <0.001) and to the concentration of amphiboles in BALF (p-value <0.001) and in a lesser extent to the chrysotile concentration in BALF (p-value = 0.03).

Serum SRMP concentration does not vary significantly between the different groups of workers divided by pathology and occupational sector.

Fibre concentration in BALF of patients non occupationally exposed to asbestos in all cases was lower than the detection limit of the method.

Table 2 shows the Confidence Intervals 95% (CIs) of concentration of amphiboles in BALF of exposed workers for each working sector and in patients with asbestosis and pleural plaques.

Table 2

**DISCUSSION**

Asbestos exposure biomarkers values (i.e. concentrations of amphiboles, chrysotile and AB in BALF) were higher in patients with asbestosis as well as in railway industry workers. Even if the population of non asbestos-exposed patients should not be considered as a control group, the negativity of fibre concentration in BALF in all cases confirms a good specificity of the analysis. According to previous studies²⁻⁴) the results confirm also that
fibre concentration in BALF can be considered as a reliable biomarker of previous asbestos exposure even after many years from the end of exposure. Statistical analysis shows that there is a relationship between higher concentration of amphiboles in BALF and the onset of non malignant asbestos-related diseases. This is particularly evident considering the highest percentage of asbestos diseases in the railway industry and the lowest one in transport sector, corresponding respectively to the highest and lowest Mean of concentration of amphiboles observed in BALF. A comprehensive review on the pathogenesis of asbestos fibrosis pointed out that the lung burden of amphiboles is the main variable in the dose-response relation between the intensity of asbestos exposure and the severity of the asbestosis\(^{16}\). Therefore exposures quantitatively similar but qualitatively different could play a different role in asbestos lung injury and the pattern of exposure seems as important as the intensity of exposure. We did not investigated the usefulness of the fibre concentration in BALF in the diagnosis of malignant mesothelioma (MM). Actually in literature there is a lack of data on this important issue. There is a number of papers concerning concentrations of AB and fibre in the lung tissue of patients with MM that demonstrated a high pulmonary burden of asbestos in the presence of a history of asbestos exposure, even many years after the cessation of exposure\(^{17-18}\). However, in the absence of specific data, it is not possible by similarity to transfer this information to the mineralogical examination of the BALF. In any case it is important to note that a “negative” non-effect outcome of the mineralogical analysis of BALF or lung tissue excludes neither potential past exposure nor the likelihood of asbestos-related disease to develop, while with “positive” results the probability of a serious health consequence is increased\(^{19-21}\).

The second significant variable with respect to working sectors and asbestos diseases is the lag time from the last asbestos exposure, that represents the “wash-out time”. In the railway industry the mean time from the last asbestos exposure is over 30 yrs. Considering other sectors such as building industry and energy production, the prevalence of asbestos-related diseases is much lower compared to amphibole concentration levels, but in those cases the time shift from the last exposure is less than 20 yrs. Therefore a follow-up of this populations for the next 10 yrs is needed in order to a quantitative comparison of asbestos diseases.

With regard to AB concentration in BALF results confirm that, as a marker of asbestos exposure, it has good specificity but a less sensibility and a poor correlation with chrysotile exposure\(^{6}\). Thus there may be cases of chrysotile-induced asbestosis without increased levels of AB as may be others without increased chrysotile lung burden because of the its higher clearence rates in comparison to amphiboles\(^{3}\).

In workers of railway industry, building industry, shipbuilding yards and electric energy production the CIs upper limit of amphibole concentration in BALF was higher than the lower limit observed in patients with
asbestosis. In the building and railway industries was found a lung burden of amphiboles respectively similar and greater to that observed in patients suffering from asbestosis.

The other variables do not differ between healthy and pathologic workers. According to a previous study\textsuperscript{22}) there is no significant difference of serum SMRP concentration in workers with asbestos-related diseases and in healthy ones. Moreover SMRP levels do not vary between different working sectors. Therefore this biomarker does not appear to be influenced by asbestos exposure levels.

**ACKNOWLEDGEMENTS**

We thank Dr. Giuseppe Marcianò (Pneumology Unit of the University Hospital of Siena) for his kind collaboration.

**REFERENCES**


Table 1. Variables measured in the studied population of 307 male workers.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>yrs from the first asbestos exposure to bronchoscopy</td>
<td>35</td>
<td>11-60</td>
</tr>
<tr>
<td>yrs from the last asbestos exposure to bronchoscopy</td>
<td>19</td>
<td>1-46</td>
</tr>
<tr>
<td>smoke habit (packs/yr)</td>
<td>22</td>
<td>0-100</td>
</tr>
<tr>
<td>% predicted FEV1</td>
<td>99</td>
<td>82-130</td>
</tr>
<tr>
<td>serum SMRP concentration (nmol/l)</td>
<td>0.8</td>
<td>0.7-4.6</td>
</tr>
<tr>
<td>BALF concentration of chrysotile (ff/ml BALF)</td>
<td>962</td>
<td>ND*-6480</td>
</tr>
<tr>
<td>BALF concentration of amphiboles (ff/ml BALF)</td>
<td>457</td>
<td>ND*-2077</td>
</tr>
<tr>
<td>BALF concentration of asbestos bodies (AB/ml BALF)</td>
<td>10</td>
<td>ND*-839</td>
</tr>
</tbody>
</table>

* Not Detectable
Table 2. Confidence Intervals 95% (CIs) of concentration of amphiboles in BALF of exposed workers in different working sectors and in patients with asbestosis and pleural plaques. CIs are computed by adopting the bias-corrected and accelerated (BCa) bootstrap\(^{10}\).

<table>
<thead>
<tr>
<th></th>
<th>Sample Mean (amphiboles/ml of BALF)</th>
<th>CIs Lower Limits (amphiboles/ml of BALF)</th>
<th>CIs Upper Limits (amphiboles/ml of BALF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Railway Industry</td>
<td>863</td>
<td>714</td>
<td>1046</td>
</tr>
<tr>
<td>Building Industry</td>
<td>512</td>
<td>406</td>
<td>650</td>
</tr>
<tr>
<td>Shipbuilding Yards</td>
<td>362</td>
<td>248</td>
<td>533</td>
</tr>
<tr>
<td>Metal Foundry</td>
<td>194</td>
<td>150</td>
<td>274</td>
</tr>
<tr>
<td>Engineering Industry</td>
<td>305</td>
<td>237</td>
<td>425</td>
</tr>
<tr>
<td>Transport</td>
<td>214</td>
<td>159</td>
<td>293</td>
</tr>
<tr>
<td>Electric Energy Production</td>
<td>397</td>
<td>318</td>
<td>563</td>
</tr>
<tr>
<td>Other Industries</td>
<td>260</td>
<td>166</td>
<td>360</td>
</tr>
<tr>
<td>ASBESTOSIS AND PLEURAL PLAQUES</td>
<td>553</td>
<td>452</td>
<td>689</td>
</tr>
</tbody>
</table>
Figure 2

- Amphiboles
- Chrysotile
- Asbestos bodies
- Total asbestos fibres

MG concentration/ML of BALF

Figure 1. Asbestos related diseases grouped for working sectors (R.I. Railway industry; S.Y. Shipbuilding Yards; B.I. Building Industry; M.F. Metal Foundry; E.I. Engineering Industry; T. Transports; E.E. Electric Energy; O.I. Other Industries).

Figure 2. Mean of concentration of amphiboles, chrysotile, asbestos bodies and total asbestos fibres/ml BALF in the professionally exposed workers grouped for working sectors (R.I. Railway industry; S.Y. Shipbuilding Yards; B.I. Building Industry; M.F. Metal Foundry; E.I. Engineering Industry; T. Transports; E.E. Electric Energy; O.I. Other Industries).